A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and skin prophylaxis aiming to prevent a skin rash

Authors :: Markus Moehler
Klaus Maria Josten
Michael Neise
Carmen Dhensaw
Holger Hebart
Claudia Lang
M. A. Woerns
Jochen Rudi
Meinolf Karthaus
Thomas Geer
Jan Wierecky
Peter R. Galle
Peter Ehscheidt
Michael Heike
Thomas Goehler
Thomas Flohr
Gerrit Dingeldein
Carl C. Schimanski
Alexander Schmittel
Source :: Journal of Clinical Oncology. 32:e20724-e20724
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: e20724 Background: Anti-EGFR empowered chemotherapeutic regimens resulted in increased overall survival (OS) and response rates (RR). Anti-EGFR induced skin rash occurs in ~ 70% patients, and ~18% ...

Subjects :: Oncology
Skin care
Cancer Research
medicine.medical_specialty
Cetuximab
Colorectal cancer
business.industry
medicine.disease
Rash
Phase IV Trial
Surgery
First line treatment
Internal medicine
medicine
FOLFIRI
Overall survival
medicine.symptom
business
medicine.drug

Full Text Access

Tools